Baird Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $27
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Mind Medicine (NASDAQ:MNMD) with an Outperform rating and set a price target of $27.
May 28, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty has initiated coverage on Mind Medicine with an Outperform rating and set a price target of $27.
The initiation of coverage with an Outperform rating and a price target significantly above the current trading price is likely to positively impact MNMD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100